A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

Simon Plummer, Stephanie Wallace, Graeme Ball, Roslyn Lloyd, Paula Schiapparelli, Alfredo Quinones-Hinojosa, Thomas Hartung, David Pamies

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

Original languageEnglish (US)
Article number1407
JournalScientific reports
Volume9
Issue number1
DOIs
StatePublished - Dec 1 2019

Fingerprint

temozolomide
Precision Medicine
Glioblastoma
Brain Neoplasms
Doxorubicin
Pharmaceutical Preparations
Neoplasms
Brain
Therapeutics
Neuroglia
Astrocytes
Histology
Apoptosis
Neurons

ASJC Scopus subject areas

  • General

Cite this

A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. / Plummer, Simon; Wallace, Stephanie; Ball, Graeme; Lloyd, Roslyn; Schiapparelli, Paula; Quinones-Hinojosa, Alfredo; Hartung, Thomas; Pamies, David.

In: Scientific reports, Vol. 9, No. 1, 1407, 01.12.2019.

Research output: Contribution to journalArticle

Plummer, Simon ; Wallace, Stephanie ; Ball, Graeme ; Lloyd, Roslyn ; Schiapparelli, Paula ; Quinones-Hinojosa, Alfredo ; Hartung, Thomas ; Pamies, David. / A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine. In: Scientific reports. 2019 ; Vol. 9, No. 1.
@article{19e0c03263764cb1add5318e5e1ee36f,
title = "A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine",
abstract = "A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30{\%} (P~0.07) and ~80{\%} (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.",
author = "Simon Plummer and Stephanie Wallace and Graeme Ball and Roslyn Lloyd and Paula Schiapparelli and Alfredo Quinones-Hinojosa and Thomas Hartung and David Pamies",
year = "2019",
month = "12",
day = "1",
doi = "10.1038/s41598-018-38130-0",
language = "English (US)",
volume = "9",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - A Human iPSC-derived 3D platform using primary brain cancer cells to study drug development and personalized medicine

AU - Plummer, Simon

AU - Wallace, Stephanie

AU - Ball, Graeme

AU - Lloyd, Roslyn

AU - Schiapparelli, Paula

AU - Quinones-Hinojosa, Alfredo

AU - Hartung, Thomas

AU - Pamies, David

PY - 2019/12/1

Y1 - 2019/12/1

N2 - A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

AB - A high throughput histology (microTMA) platform was applied for testing drugs against tumors in a novel 3D heterotypic glioblastoma brain sphere (gBS) model consisting of glioblastoma tumor cells, iPSC-derived neurons, glial cells and astrocytes grown in a spheroid. The differential responses of gBS tumors and normal neuronal cells to sustained treatments with anti-cancer drugs temozolomide (TMZ) and doxorubicin (DOX) were investigated. gBS were exposed to TMZ or DOX over a 7-day period. Untreated gBS tumors increased in size over a 4-week culture period, however, there was no increase in the number of normal neuronal cells. TMZ (100 uM) and DOX (0.3 uM) treatments caused ~30% (P~0.07) and ~80% (P < 0.001) decreases in the size of the tumors, respectively. Neither treatment altered the number of normal neuronal cells in the model. The anti-tumor effects of TMZ and DOX were mediated in part by selective induction of apoptosis. This platform provides a novel approach for screening new anti-glioblastoma agents and evaluating different treatment options for a given patient.

UR - http://www.scopus.com/inward/record.url?scp=85061124735&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85061124735&partnerID=8YFLogxK

U2 - 10.1038/s41598-018-38130-0

DO - 10.1038/s41598-018-38130-0

M3 - Article

VL - 9

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 1407

ER -